BGM Group Ltd is a Cayman Islands holding company that conducts its pharmaceutical and chemical business in China through contractual arrangements with Gansu Qilianshan Pharmaceutical Co., Ltd. and its subsidiaries. The company focuses on the development manufacture marketing and sale of products such as oxytetracycline licorice extracts traditional Chinese medicine derivatives heparin sausage casings and fertilizers while also pursuing initiatives in artificial intelligence intelligent robots algorithmic computing power cloud computing and biopharmaceuticals.

BGM Group Ltd generates revenue mainly from selling its pharmaceutical and chemical products to distributors dealers and corporate customers across China. In addition the company receives a service fee equal to 99.214 percent of the net profits of Gansu Qilianshan Pharmaceutical Co., Ltd. under its variable interest entity agreements.

BGM Group Ltd operates in a competitive landscape that includes domestic manufacturers of oxytetracycline licorice heparin sausage casings and fertilizers. The company cites its western China location its unique product mix and its lower prices as key advantages. It also benefits from a portfolio of patents trademarks and a nationally recognized enterprise technology center that support its research and development efforts.

BGM Group Ltd serves a broad customer base that includes distributors dealers and corporate customers. Specific numbers disclosed in the filing show five corporate customers for heparin product eleven corporate customers for sausage casings two distributors and thirty two dealers for fertilizer products thirty distributors and two dealers for oxytetracycline API and one hundred eighty nine distributors and one dealer for oxytetracycline tablets and licorice products.